Skip to main content
. 2019 Dec 17;21(Suppl K):K21–K28. doi: 10.1093/eurheartj/suz205

Figure 1.

Figure 1

The burden of comorbidities observed across pulmonary hypertension groups at the time of diagnosis in authors’ experience.18–21aComorbidities that are typically associated with pulmonary hypertension Group 5, but may affect all groups. bComorbidities that are typically associated with IPAH, but may affect all groups. This schematic is used to illustrate the typical scenarios the authors observe in clinic; it is not drawn to scale and is largely based on authors own experience rather than a robust body of evidence in the literature. The blue triangle and the rectangular ‘Group’ boxes represent the burden of comorbidity and thus, the placement of the pulmonary hypertension group boxes within the triangle, as well as their size, represent the relative prevalence of comorbidities in each group (with the lowest and largest group having the greatest prevalence). Group 5 pulmonary hypertension is shown outside the triangle because published data and the authors’ findings from the clinic are not sufficient to draw conclusions from; there is no consensus on the prevalence of comorbidities in Group 5 pulmonary hypertension at the time of diagnosis. COPD, chronic obstructive pulmonary disease; IPAH, idiopathic pulmonary arterial hypertension; PH, pulmonary hypertension.